环氧合酶 1 抑制剂市场 - 按类型（选择性 Cox 1 抑制剂、非选择性 Cox 1 抑制剂）、应用（发炎性疾病、胃肠道毒性、癌症化学预防）、配销通路- 全球预测（ 2024 年- 2032 年）

由于人口老化的成长和对疼痛管理选择的认识不断提高，2024年至2032年全球环加氧酶1抑制剂市场规模将创下7.6%的复合年增长率。环加氧酶 1 抑制剂透过靶向产生前列腺素的 COX-1 酶来减轻疼痛和发炎。

药物研究的进步正在推动新型 COX-1 抑制剂的开发，其安全性和功效均得到改善。此外，持续的发展确保 COX-1 抑制剂仍然是管理与老化相关的健康问题不可或缺的一部分。根据《2022年世界人口展望》，65岁以上人口的成长速度快于年轻族群。这种人口结构的变化正在增加治疗与年龄相关的疼痛和发炎的产品需求。

环氧合酶 1 抑制剂产业按类型、应用、配销通路和地区划分。

就类型而言，到 2032 年，非选择性 Cox 1 抑制剂领域的行业规模将大幅增长。研究人员正在探索非选择性 Cox 1 抑制剂对胃肠道健康的影响，因为它们会影响胃壁并导致不良副作用。此外，持续的进步正在改进非选择性 COX-1 抑制剂的配方，以在保持有效性的同时增强其安全性。

从应用来看，由于使用量不断增加以优化效益并最大限度地减少潜在副作用，预计从 2024 年到 2032 年，环氧合酶 1 抑制剂在癌症化学预防领域的市占率将会上升。 COX-1 抑制剂（例如阿斯匹灵）能够阻断 COX-1 酶活性，而 COX-1 酶活性与发炎和肿瘤进展有关。研究人员也关注 COX-1 抑制剂如何透过阻止可促进肿瘤发展的发炎性前列腺素的形成来降低癌症风险。

从地区来看，在不断增长的药品组合和药物输送系统进步的推动下，欧洲环氧合酶 1 抑製剂行业规模预计将在 2024 年至 2032 年间实现强劲增长。阿斯匹灵和布洛芬等 COX-1 抑制剂在很大程度上被整合到更广泛的疼痛和发炎治疗中，进一步反映了它们的多功能性和有效性。同时，药物传递系统的改进正在增强 COX-1 抑制剂的功效和安全性，以确保该地区更好的吸收和有针对性的作用。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 发炎性疾病盛行率增加
    • 药物开发的技术进步
    • 癌症盛行率上升
    • 提高认识和诊断
  • 产业陷阱与挑战
    • 不良反应和安全问题
• 成长潜力分析
• 报销场景
• 监管环境
• 技术景观
  • 核心技术
  • 邻近技术
• 2023 年定价分析
  • 按地区
  • 按关键人物
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 选择性cox 1抑制剂
• 非选择性 Cox 1 抑制剂

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 发炎性疾病
• 胃肠道毒性
• 癌症化学预防
• 其他应用

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AbbVie Inc.
• Alembic Limited
• Aurobindo Pharma Limited
• Boehringer Ingelheim International GmbH
• Bayer AG
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Sabinsa
• Teva Pharmaceutical Industries Ltd
• Torrent Pharmaceuticals Limited
• Viatris Inc.
• Zydus Lifesciences Limited

Global Cyclooxygenase 1 Inhibitor Market size will record 7.6% CAGR from 2024 to 2032, due to the growth of the aging population and increasing awareness of pain management options. Cyclooxygenase 1 inhibitors are used to reduce pain and inflammation by targeting the COX-1 enzyme for producing prostaglandins.

Advances in pharmaceutical research are leading to the development of new COX-1 inhibitors with improved safety profiles and efficacy. Furthermore, ongoing evolution is ensuring that COX-1 inhibitors remain integral to managing health issues associated with aging. According to the World Population Prospects 2022, the population above the age of 65 years is growing more rapidly than younger age groups. This demographic shift is increasing the product demand for managing age-related pain and inflammation.

The cyclooxygenase 1 inhibitors industry is segregated into type, application, distribution channel, and region.

In terms of type, the industry size from the non-selective Cox 1 inhibitor segment is set to experience growth at a significant rate through 2032. This is owing to the strong need to address pain and inflammation by inhibiting the COX-1 enzyme. Researchers are exploring the effects of non-selective Cox 1 inhibitors on gastrointestinal health as they can affect the stomach lining and lead to adverse side effects. In addition, ongoing advancements are improving the formulations of non-selective COX-1 inhibitors to enhance their safety profiles while maintaining effectiveness.

By application, the cyclooxygenase 1 inhibitor market share from the cancer chemoprevention segment is projected to rise from 2024 to 2032, fueled by rising usage to optimize the benefits and minimize potential side effects. COX-1 inhibitors, such as aspirin offer the ability to block COX-1 enzyme activity, which is involved in inflammation and tumor progression. Researchers are also focusing on how COX-1 inhibitors might reduce cancer risk by preventing the formation of inflammatory prostaglandins that can promote tumor development.

Regionally, the Europe cyclooxygenase 1 inhibitor industry size is projected to register robust growth between 2024 and 2032, driven by growing pharmaceutical portfolio and advancements in drug delivery systems. COX-1 inhibitors like aspirin and ibuprofen are largely integrated into a wider range of treatments for pain and inflammation, further reflecting their versatility and effectiveness. Simultaneously, improvements in drug delivery systems are enhancing the efficacy and safety of COX-1 inhibitors for ensuring better absorption and targeted actions in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of inflammatory diseases
    • 3.2.1.2 Technological advancements in drug development
    • 3.2.1.3 Rising prevalence of cancer
    • 3.2.1.4 Increasing awareness and diagnosis
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
  • 3.6.1 Core technologies
  • 3.6.2 Adjacent technologies
• 3.7 Pricing analysis, 2023
  • 3.7.1 By region
  • 3.7.2 By key player
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Selective cox 1 inhibitor
• 5.3 Non-selective Cox 1 inhibitor

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Inflammatory diseases
• 6.3 Gastrointestinal toxicity
• 6.4 Cancer chemoprevention
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Alembic Limited
• 9.3 Aurobindo Pharma Limited
• 9.4 Boehringer Ingelheim International GmbH
• 9.5 Bayer AG
• 9.6 Cipla Limited
• 9.7 Hikma Pharmaceuticals PLC
• 9.8 Johnson & Johnson
• 9.9 Novartis AG
• 9.10 Pfizer Inc.
• 9.11 Sabinsa
• 9.12 Teva Pharmaceutical Industries Ltd
• 9.13 Torrent Pharmaceuticals Limited
• 9.14 Viatris Inc.
• 9.15 Zydus Lifesciences Limited